Evaluation of post-vaccination humoral immune response against SARS-CoV-2
Abstract
Abstract:
Background: The new variant of Coronavirus SARS-CoV-2 is responsible for the COVID-19 pandemic. Currently, there is no curative treatment available for this virus. Therefore, researchers have developed several types of vaccinations.The evaluation of the post-vaccination humoral response is essential in determining vaccine efficiency and formulating an efficient vaccination plan .Algeria has adopted a vaccine strategy involving inactivated vaccines (SINOVAC and SINOPHARM) and vector vaccines (SPUTNIK V, ASTRAZENECA, and JENSSEN).
Objective: The main objective of this study is to investigate the humoral immune responses after administering two doses of the same available COVID-19 vaccine (Sputnik V, Sinopharm, or Sinovac) among workers at Mustapha Bacha Hospital. Additionally, the impact of key factors related to immunity, including a person’s age, sex, previous COVID-19 infection, neutralizing capacity according to the type of vaccine and the interval following the second dose, was also explored.
Results: The seroprevalence of IgG anti-S1 RBD was found to be approximately 93.4%, 93.6%, and 90.7% for SINOVAC, SINOPHARM, and SPUTNIK V, respectively. The average rates of IgG anti-S1 RBD were higher in the SPUTNIK V group. Different factors such as age and prior SARS-CoV-2 infection influenced the humoral response to some vaccines separately. The neutralizing capacity of IgG anti-S1 RBD was positive in 72% of participants vaccinated with SINOVAC and SPUTNIK V.
Conclusion: It is crucial to focus on the longevity of the vaccines immune response at this time. The findings from various studies may help make decisions about the efficiency of vaccines, introduction of a booster dose, and prioritizing the high-risk population.
References
2. Wang M-Y, Zhao R, Gao L-J, Gao X-F, Wang D-P and Cao J-M (2020) SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front. Cell. Infect. Microbiol. 10:587269. doi: 10.3389/fcimb.2020.587269.
3. https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions.
4. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 14 mai 2020;181(4):894-904.e9.
5. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 13 mars 2020;367(6483):1260‑3.
6. Bonny V, Maillard A, Mousseaux C, Plaçais L, Richier Q. COVID-19 : physiopathologie d’une maladie à plusieurs visages. La Revue de Médecine Interne [Internet]. juin 2020 [cité 26 août 2022];41(6):375‑89. Disponible sur: https://linkinghub.elsevier.com/retrieve/pii/S0248866320301648
7. Antibody Responses to SARS-CoV-2: Let’s Stick to Known Knowns - PubMed [Internet]. [cité 31 août 2022]. Disponible sur: https://pubmed.ncbi.nlm.nih.gov/32887754/
8. Corroyer-Simovic B, Lefevre G, Demaret J, Labalette M, Alidjinou E, Goffard A, et al. Résultats préliminaires de l’évaluation de la réponse immunitaire du vaccin anti-SARS-CoV2 BNT162b2 chez le sujet âgé versus l’immunité naturelle post-COVID. Infectious Diseases Now [Internet]. août 2021 [cité 18 oct 2022];51(5):S25. Disponible sur: https://linkinghub.elsevier.com/retrieve/pii/S2666991921001652
9. World Health Organization. Draft landscape of COVID-19 candidate vaccines. 2020. Available at: https://www.who.int/publications/m/item/draft-landscape-ofcovid-19-candidate-vaccines. Accessed 6 October 2021.
10.Krammer F. SARS-CoV-2 vaccines in development. Nature 2020; 586:516–27. Available at: http://www.nature.com/articles/s41586-020-2798-3.
11.Covid-19: l’immunité collective et la vaccination à l’origine de la stabilité des contaminations [Internet]. [cité 25 oct 2022]. Disponible sur: https://www.aps.dz/sante-science-technologie/141681-covid-19-l-immunite-collective-et-la-vaccination-a-l-origine-de-la-stabilite-des-contaminations
12.Covid-19 : poursuivre la vaccination de la population pour prévenir de nouvelles reprises épidémiques [Internet]. [cité 25 oct 2022]. Disponible sur: https://www.aps.dz/sante-science-technologie/139696-covid-19-poursuivre-la-vaccination-de-la-population-pour-prevenir-de-nouvelles-reprises-epidemiques
13.Infantino M, Damiani A, Gobbi FL, Grossi V, Lari B, Macchia D, et al. Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. Isr Med Assoc J. avr 2020;22(4):203‑10.
14.Mallapaty S. Will antibody tests for the coronavirus really change everything? Nature [Internet]. 30 avr 2020 [cité 28 août 2022];580(7805):571‑3. Disponible sur: https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=00280836&v=2.1&it=r&id=GALE%7CA622295759&sid=googleScholar&linkaccess=abs
15.Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet [Internet]. [cité 28 août 2022]. Disponible sur: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext
16.Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. oct 2020;586(7830):594‑9.
17. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity - PubMed [Internet]. [cité 28 août 2022]. Disponible sur: https://pubmed.ncbi.nlm.nih.gov/32726802/
18. Serology assays to manage COVID-19 - PubMed [Internet]. [cité 28 août 2022]. Disponible sur: https://pubmed.ncbi.nlm.nih.gov/32414781/
19. Tests de détection d’anticorps pour COVID-19 (ELISA) [Internet]. [cité 31 août 2022]. Disponible sur: https://www.coronavirus-diagnostics.com/antibody-detection-tests-for-covid-19.html
20. Scholz DJ. EUROIMMUN Launches SARS-CoV-2 NeutraLISA Assay to Determine the Neutralizing Capacity of Anti-SARS-CoV-2 Antibodies [Internet]. EUROIMMUNBlog. 2021 [cité 31 août 2022]. Disponible sur: https://www.euroimmunblog.com/sars-cov-2-neutralisa-to-determine-neutralizing-antibodies/
21. KIHELI. M. EVALUATION DE LA REPONSE HUMORALE DES VACCINS ANTI SARS COV-2 CHEZ UN GROUPE DE SUJETS ALGERIENS. 2021;
22. Abrouk S et al. Enquete menée auprès des sujets vaccinés au Sputnik v à l’instituT pasteur d’Alger. 23 déc 2021;
23. Cucunawangsih C, Wijaya RS, Lugito NPH, Suriapranata I. Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers, Indonesia. International Journal of Infectious Diseases [Internet]. déc 2021 [cité 26 août 2022];113:15‑7. Disponible sur: https://linkinghub.elsevier.com/retrieve/pii/S1201971221007876
24. Chahla RE, Tomas-Grau RH, Cazorla SI, Ploper D, Vera Pingitore E, López MA, et al. Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina. The Lancet Regional Health - Americas [Internet]. février 2022 [cité 26 août 2022];6:100123. Disponible sur: https://linkinghub.elsevier.com/retrieve/pii/S2667193X21001198
25. Bueno SM, Abarca K, González PA, Gálvez NMS, Soto JA, Duarte LF, et al. Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile. Clinical Infectious Diseases [Internet]. 24 août 2022 [cité 26 août 2022];75(1):e792‑804. Disponible sur: https://academic.oup.com/cid/article/75/1/e792/6372423
26. Dashdorj NJ, Wirz OF, Röltgen K, Haraguchi E, Buzzanco AS, Sibai M, et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host & Microbe [Internet]. déc 2021 [cité 26 août 2022];29(12):1738-1743.e4. Disponible sur: https://linkinghub.elsevier.com/retrieve/pii/S1931312821005102
27. Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N, Ruenjaiman V, et al. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac J Allergy Immunol. sept 2022;40(3):269‑77.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
